Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation

Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
  • CureVac N.V.  CVAC and GSK plc GSK have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination.
  • The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac's "second-generation mRNA backbone" to develop the vaccine.
  • CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single booster dose in the dose range of 12µg to 50µg at first.
  • Related: BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac.
  • Additional dose levels below 12µg and above 50µg may be evaluated if supported by safety and immunogenicity data at these dose levels.
  • In March, the company also kicked off a phase 1 test for a "second-generation" COVID-19 shot called CV2CoV.
  • The company said this double-pronged approach would help identify the best-performing candidate for later-stage clinical development.
  • Data from the two studies will be reported together, although CureVac did not say when. 
  • Price Action: CVAC shares are down 0.08% at $13.17, and GSK stock is down 1.92% at $34.04 on the last check Thursday.
  • Photo by Gerd Altmann from Pixabay

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechLarge CapNewsHealth CareGeneral